



Celgene has announced the appointment of **Alise Reicin** (left) as president, global clinical development. Reicin was most recently senior vice president and head of global clinical development in R&D at EMD Serono, the biopharmaceutical business of Merck KGaA. Since joining EMD Serono in 2015, she has led clinical development, biostatistics, clinical operations and the Japan and China R&D hubs.

“Dr. Reicin is an accomplished physician with an excellent record of developing important therapeutics for multiple cancer and inflammatory indications,” said Mark J. Alles, chairman and CEO of Celgene. “Led by Alise, our clinical development organization will be structured to more completely align with our strategy and mission to discover, develop and commercialize innovative therapies for patients with unmet need.”

Millendo Therapeutics has named **Louis Arcudi III** as chief financial officer and **Michael Yeh** as vice president of medical affairs. Arcudi brings over 20 years of financial and operational experience to Millendo, serving most recently as senior vice president of operations and CFO at Idera Pharmaceuticals. Yeh has a decade of life science industry experience, most recently as head of medical affairs for General Electric healthcare life sciences core imaging for the US and Canada.

London-based clinical-stage gene therapy company MeiraGTx has named **Katherine Breedis** as chief financial officer. Prior to joining MeiraGTx, Breedis was a managing director, equity research, and senior analyst for biotechnology and major pharmaceuticals with Stifel Nicolaus & Company.

Joseph DeRisi, professor of biochemistry and biophysics at the University of California, San Francisco and co-president of Chan Zuckerberg Biohub, has been appointed to the uBiome board of directors. DeRisi is a MacArthur Fellowship-winning biochemist and a pioneer of DNA microarray technology and whole-genome expression profiling.

Ellen G. Feigal has been named a director of clinical-stage biopharmaceutical company Xencor. Formerly senior vice president of R&D at the California Institute for Regenerative Medicine; executive medical director, global development at Amgen; and chief medical officer at Insys Therapeutics, Feigal is currently a partner at NDA Partners, a strategy consulting firm.

Sarah Gould has been named chief development officer of anti-infective drug developer Nosopharm (Lyon, France). She brings over 20 years' experience in non-clinical pharmacology and toxicology, most recently at Adocia, where she was non-clinical director for pharmacology and toxicology. Before this, Gould worked as senior director for non-clinical safety at Sanofi Pasteur and held several positions at AstraZeneca UK.

Jnana Therapeutics has appointed **Joanne Kotz** as CEO. Kotz cofounded Jnana in January 2017 and has served as president for the last year. She was previously assistant director of F-Prime Capital Partners' biomedical research initiative that focused on early-stage neurodegeneration. Before that, she served as director of the Broad Institute's Center for the Science of Therapeutics.

Gary Lee has joined synthetic biology platform company Senti Biosciences as its new chief scientific officer. A 13-year veteran of Sangamo Therapeutics, Lee served most recently vice president of cell therapy.

Nektar Therapeutics has announced the appointment of **Wei Lin** as senior vice president of clinical development and head of Nektar's oncology programs. Lin was most recently at Genentech, where he served as the global development leader for cancer immunotherapy in lung and head and neck cancer.

Stephen Mitchener has been appointed senior vice president and chief business officer of Axcella Health. He brings 15 years of pharma industry experience, most recently

as head of US oncology strategy, partnering and operations at Novartis Pharmaceuticals.

Hookipa Pharma has announced the appointment of **Julie O'Neill** as a non-executive director. O'Neill was formerly executive vice president, global operations at Alexion Pharmaceuticals. Before joining Alexion, she was vice president of operations at Gilead Sciences.

Sutro Biopharma has announced the appointment of **Shalini Sharp** to its board of directors. Sharp brings over 20 years of experience in the life sciences industry covering strategic financial planning, corporate and business development, risk analysis and investor relations. She is currently CFO and executive vice president of Ultragenyx Pharmaceutical.

SomaLogic has appointed **Roy Smythe** as CEO. Smythe is a surgeon and former translational scientist who joins the company from Royal Philips, where he served as chief medical officer for strategy and partnerships. Before joining Philips, he was chief medical officer at Valence Health and AVIA.

Precision oncology company Strata Oncology has named **Scott A. Tomlins** chief medical officer. Tomlins is a molecular pathologist and cancer genomics researcher who was most recently an associate professor of pathology at the University of Michigan, where his research focused on using high-throughput techniques to characterize the cancer genome and transcriptome to understand cancer biology and identify clinically relevant biomarkers and therapeutic targets.

Seres Therapeutics has announced the appointment of Kevin Horgan as executive vice president and chief medical officer, succeeding **Michele Trucksis**, who will continue to provide consulting services to the company. Most recently, Horgan was vice president of clinical development at AstraZeneca. He earlier cofounded Tucana Health and held chief medical officer roles at Soligenix and Coronado.

Matoke Pharma has named **Alan Westwood** as managing director. Westwood was formerly vice president of global strategic marketing for anti-infectives at Bayer Health Care.